News & Events

shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces First Quarter Results,” issued by the Company on May 5, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORATORIES,…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On March 24, 2026, IDEXX Laboratories, Inc. (“IDEXX”) and Nimrata Hunt, PhD, Executive Vice President, Global Strategy and Commercial, mutually agreed that Dr. Hunt will cease serving in her current role effective on April 13, 2026 (the “Separation Date”) and will continue to provide advisory services on an as-needed basis until July 13, 2026 (the “…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On February 13, 2026, Ms. M. Anne Szostak provided IDEXX Laboratories, Inc. (the “Company”) notice of her intention to retire from the Board of Directors (the “Board”) effective immediately following the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) to be held on May 12, 2026. Ms. Szostak’s decision to retire from th…

shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results,” issued by the Company on February 2, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly auth…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On February 13, 2025, Dr. Asha Collins resigned from the Board of Directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”), effective immediately. Dr. Collins’s decision to resign was not the result of any disagreement with the Company on any matters relating to the Company’s operations, policies or practices. The Company and Board t…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Adoption of Nonqualified Deferred Compensation Plan On December 6, 2024, the Board of Directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”), upon the recommendation of the Compensation and Talent Committee of the Board (the “Committee”), approved and adopted the IDEXX Deferred Compensation Plan (the “Plan”). The Plan constitutes an un…

Entry into a Material Definitive Agreement. Effective as of October 31, 2024, IDEXX Laboratories, Inc. and certain of its affiliates entered into: (i) an Amendment No. 9 (the “U.S. Amendment”) to the Agreement effective as of October 16, 2003 between IDEXX Operations, Inc. and Ortho-Clinical Diagnostics, Inc. (“Ortho”), as amended by Amendment Nos. 1 to 8 and the Letter Agreement dated July 28, 2023 (the “Original U.S. Supply Agreement” and as amended by the U.S. Amendment, the “U.S. Supply A…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 5, 2023, James F. Polewaczyk, Executive Vice President and Chief Commercial Officer of IDEXX Laboratories, Inc. (the “Company”), notified the Company of his intent to retire after more than 17 years of dedicated leadership and service, effective April 1, 2024. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 193…

Regulation FD Disclosure IDEXX Laboratories, Inc. (NASDAQ: IDXX) (“IDEXX”) is furnishing this Current Report on Form 8-K to provide further information regarding its operations in Russia. Since March 2022, IDEXX has significantly scaled back its operations in Russia, including the suspension of sales of veterinary diagnostic equipment; promotional, marketing, and hiring activities; and new business development and related investments. IDEXX’s 2021 annual revenue in Russia represented less tha…